Pharmaceutical Executive-04-01-2018

Amid rapid shifts in technology and consumer engagement, Pharm Exec explores how new models in hiring and recruitment-along with the evolution of the C-suite-are reshaping biopharma’s talent path of the future.

Senior leaders in the life sciences share stories on making the jump from the pharma to biotech worlds-and the innate drivers behind such moves.

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

FDA is moving slowly in liberalizing off-label communications amid outrage over opioid promotion.

Looking at the balance of optimism and caution discussed at eyeforpharma Barcelona around pharma’s embrace of AI.

Pharma's evolving landscape in recent years has created the need to recruit experts from outside of industry-and establish new pathways for traditional executive roles in the life sciences.

From her early calling as a doctor to assuming critical leadership roles at the front lines of the world’s most pressing population health issues, Julie Gerberding, this year's Healthcare Businesswomen’s Association Woman of the Year, has remained steadfast in her life’s mission-help the many, help the one.

Three ways AR can bolster pharma commercialization strategies.

The role of the medical affairs professional in the biopharma hierarchy has grown considerably in recent years, but challenges remain in its accent to true strategic partner with the C-suite.

And ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment

Looking back at the agenda of a 1985 EFPIA conference demonstrates that, three decades on, the European drug industry is still seeking a pill for its own ills.

Outlining the four major areas driving China’s life sciences industry, which may be on the cusp of a new era in R&D and healthcare reform.     

To attract the best talent, offer a workplace that inspires.

Still motivated by its challenging, underdog past, Poland has strengthened its economic engine in Europe, where the nation’s pharmaceutical sector is increasingly pursuing enlightened approaches in areas such as market access and evidence-based decision-making.

Click the title above to open the Pharmaceutical Executive April 2018 issue in an interactive PDF format.